GLUCOTRACK ANNOUNCES NEW VP OF MARKETING
August 28 2023 - 9:00AM
Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a
medical device company focused on glucose monitoring technologies
for people with diabetes and prediabetes, announced today that
Drinda Benjamin has joined the company as Vice President of
Marketing.
Ms. Benjamin has over 20 years of experience in
life sciences, with specific focus on commercialization of health
technology. Within diabetes, she has past experiences in product
development, strategic marketing, and both upstream and downstream
marketing in the areas of blood glucose monitoring, continuous
glucose monitoring (CGM), insulin delivery and closed loop systems.
Ms. Benjamin was most recently with Intuity Medical where she
developed and executed commercial strategies for a novel integrated
blood glucose monitoring system. Prior to this, she led business
development, partnership strategy and closed loop system programs
for Senseonics, manufacturer of the 1st implantable CGM launched in
the US and Europe. She has also held marketing roles with Abbott
Diabetes Care and Medtronic Diabetes.
“We are excited that Drinda has joined our
growing company in this important leadership role.” said Paul
Goode, CEO of Glucotrack. “She brings a wealth of first-hand
experience in product and strategic development within the diabetes
space, particularly with spot-measurement BGM and implantable CGM.
As we continue our product development and prepare for
commercialization, we are pleased to have Drinda join to help the
company bring our innovative technology to people with
diabetes.”
Ms. Benjamin will be responsible for
go-to-market strategy, marketing operations, company
communications, public relations and market access strategy. “I am
thrilled to be a part of the dedicated Glucotrack team.” said Ms.
Benjamin. “Innovations in glucose monitoring have significantly
improved quality of life for people with diabetes. But there still
is an opportunity to build upon current technologies and bring new
ones to the millions of people living with diabetes. Glucotrack’s
early data shows great promise to deliver on that opportunity.”
Ms. Benjamin earned an M.B.A. from Georgetown
University’s McDonough School of Business and a Bachelor of Science
in Engineering degree from Princeton University.
About Glucotrack,
Inc.
Glucotrack, Inc. (NASDAQ: GCTK), (formerly known
as Integrity Applications, Inc.) is focused on the design,
development, and commercialization of novel technologies for people
with diabetes and prediabetes. The Company’s initial product,
Glucotrack®, is a proprietary non-invasive glucose monitoring
device designed to obtain glucose level measurements without the
pain, incremental cost, difficulty, or discomfort of conventional
invasive finger stick devices. For more information, please visit
and http://www.glucotrack.com.
Investor Contact: investors@glucotrack.com
Forward-Looking Statements
This news release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements contained in this news release that
are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the generality of the
foregoing, words such as “expect”, “plan” and “will” are intended
to identify forward-looking statements. Readers are cautioned that
certain important factors may affect Glucotrack’s actual results
and could cause such results to differ materially from any
forward-looking statements that may be made in this news release.
Factors that may affect Glucotrack’s results include, but are not
limited to, the ability of GlucoTrack to raise additional capital
to finance its operations (whether through public or private equity
offerings, debt financings, strategic collaborations or otherwise);
risks relating to the receipt (and timing) of regulatory approvals
(including FDA approval); risks relating to enrollment of patients
in, and the conduct of, clinical trials; risks relating to its
current and future distribution agreements; risks relating to its
ability to hire and retain qualified personnel, including sales and
distribution personnel; and the additional risk factors described
in Glucotrack’s filings with the U.S. Securities and Exchange
Commission (the “SEC”), including its Annual Report on Form 10-K
for the year ended December 31, 2022 as filed with the SEC on March
31, 2023.
GlucoTrack (NASDAQ:GCTK)
Historical Stock Chart
From Apr 2024 to May 2024
GlucoTrack (NASDAQ:GCTK)
Historical Stock Chart
From May 2023 to May 2024